WO2023018812 - HETEROCYCLIC COMPOUNDS AND METHODS OF USE
National phase entry:
Publication Number
WO/2023/018812
Publication Date
16.02.2023
International Application No.
PCT/US2022/039971
International Filing Date
10.08.2022
Title **
[English]
HETEROCYCLIC COMPOUNDS AND METHODS OF USE
[French]
COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION
Applicants **
AMGEN INC.
Inventors
YAMANO, Michael M.
LI, Yunxiao
NAVARATNE, Primali
MEDINA, Jose
CHEN, Ning
PETTUS, Liping
RAHIMOFF, Rene
LI, Xiaofen
STELLWAGEN, John
MANONI, Francesco
LI, Kexue
LANMAN, Brian Alan
WURZ, Ryan Paul
ZHAO, Wei
RUI, Huan
ESHON, Josephine
Priority Data
63/231,543
10.08.2021
US
63/289,579
14.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5793 | |
| EPO | Filing, Examination, Granting | 44640 | |
| Japan | Filing, Examination, Granting | 3432 | |
| South Korea | Filing, Examination, Granting | 4651 | |
| USA | Filing, Examination, Granting | 16560 |
Total:
75,076
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula (I) : wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.[French]
La présente invention concerne des composés utiles pour l'inhibition de KRAS G12D. Les composés ont une formule générale (I), les variables de la formule I étant définies dans la description. L'invention concerne également des compositions pharmaceutiques comprenant les composés, des utilisations des composés et des compositions pour traiter par exemple le cancer.